ESIS of adenine and guanine ribonucleosides, precursors of DNA and RNA. They are classified as drugs in the FDA pregnancy category D. For oral administration is 47% of AZA into the systemic circulation, w While only 16% of the MP is available. 57 These were shown to be effective in the treatment of stero Be dependent on Ngigen or resistant IBD.58 These medicines as immunosuppressive therapy in autoimmune diseases, transplant patients and leukemia Chemistry used. Safety of azathioprine may need during the pregnancy has been demonstrated in studies of transplant recipients and rheumatology. The F Will not do inosinate phosphorylase enzyme, the ben To do prior to convert AZA and MP active metabolites, and thus is protected from m Possible teratogenic effects of AZA and MP. Small doses of these drugs do not appear to adversely affect human health reproduction.59, 60 In a retrospective study of patients U member again for IBD had before and may need during the chemical compound library execution relative to the control group, n “There was no statistical difference in conception failure, increases ht abortion due to birth defects, big en malformations, tumors or infections, P 0, 59) .61 In a recent prospective, multicenter controlled EAA from, the University of t Tel Aviv carried out, there wasno increase in birth defects, but there was more of prematurity and low birth weight in the AZA-treated women.62 A large s national cohort study of d African women who had increased to azathioprine or MP w while exposed during pregnancy ht the overall risk of preterm birth, low birth weight babies at term and birth defects in newborns of AZA or MP-exposed women, but when the comparison was the women with the same type of underlying disease, only the risk of preterm birth induced remained highly limited.
The authors’ conclusion was that the side effects of underlying disease t like drug pleased induced.63 However, in a study of 900 children born to women with CD were created 1996-2004, the risk of premature birth and congenital anomalies in exposed women were 4.2 and 2.9 and thiopurine, these risks remained high even after adjusting for confounders.64 However, some of basic conclusions of this study surveyed the problems with a confidence interval of difference, lack of prim Ren endpoint and the bias of the confusion by stating the pharmacotherapy of the disease activity.65 A retrospective Swedish registry AKT Signaling Pathway that patients azathioprine may need during the pregnancy, the comment rate of congenital malformations was 6.2% in the AZA group and 4.7% of all newborns. S uglinge exposed to AZA were more premature, had weight 2500 g, small for gestational age and an increased HTES risk for birth defects. AZA in early pregnancy exposure was with ventricular ren / atrial septal defect associated note. The authors note that m for may have a correlation between the severity of the disease and the use of drugs that the results.66 In a recent study, controlled exposure of 19 births can to be on The AZA / MP, 74, was the use of AZA / MP is not an obtainable Hten risk of giving birth to low birth weight and preterm term, adverse effects or congenital neonatal anomalies.67 the reporting hnlichen results the results of 215 pregnancies associated with 204 women who were from a cohort study in France, was Publishe CESAME.